www.menveohcp.com Open in urlscan Pro
34.107.225.66  Public Scan

Form analysis
1 forms found in the DOM

GET /search-results/

<form action="/search-results/" method="get"> <label for="q"><input type="text" name="q" maxlength="2048" placeholder=" "></label><button type="submit" aria-label="Search">SEARCH</button>
  <input name=":cq_csrf_token" type="hidden" value="undefined">
</form>

Text Content

LEAVING MENVEO HCP SITE

You are about to leave a GSK website. By clicking this link, you will be taken
to a website that is independent from GSK. The site you are linking to is not
controlled or endorsed by GSK, and GSK is not responsible for the content
provided on that site.

Continue Cancel

You are using an unsupported browser.

Some features of this site may not function properly. For optimal user
experience, please view this site in Chrome, Firefox, Safari, or Edge.

Close

Sorry, your browser window is too small.

Some features of this site may not function properly. For optimal user
experience, please view this site in a larger browser window.

Close

Dear Healthcare Provider Letter

For US Healthcare ProfessionalsFor US HCPs
Prescribing Information Prescribing Info GSKMedInfo
HCP Branded with Claims
SEARCH
Tell us what you are looking for in the search box.
CTA
 * Meningococcal Disease
 * CDC Recommendations
 * Dosing & Administration
 * Immunogenicity
   * Adolescents
   * Booster
   * 1-Vial Presentation
   * Infants and Toddlers
 * Safety
 * Global Heritage

 * Visit US Patient Site
 * GSKMedInfo



The persons depicted are models used
for illustrative purposes only.

The persons depicted are models used for illustrative purposes only.

...IT’S TIME FOR A BOOSTER DOSE

 * MENVEO 1-vial presentation is approved for use in individuals 10 through 55
   years of age1
 * MENVEO 2-vial presentation is approved for use in individuals 2 months
   through 55 years of age1


ADOLESCENTS ARE CONSTANTLY CHANGING—BUT THEIR NEED FOR VACCINATION DOES NOT


ADOLESCENTS ARE CONSTANTLY CHANGING—
BUT THEIR NEED FOR VACCINATION DOES NOT

While your patients may have received a primary dose of a meningitis ACWY
(MenACWY) vaccine at age 11-12, it's time to follow up and fulfill the CDC
recommendations for adolescents—with a booster dose at 16 years of age.2,3

INDICATION

MENVEO is a vaccine indicated for active immunization to prevent invasive
meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and
W-135 in individuals 2 months through 55 years of age. MENVEO does not prevent
N. meningitidis serogroup B infections.

INDICATION

MENVEO is a vaccine indicated for active immunization to prevent invasive
meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and
W-135 in individuals 2 months through 55 years of age. MENVEO does not prevent
N. meningitidis serogroup B infections.

 -



Be sure to check your records

According to 2021 CDC survey data, 91% of 17-year-olds had received a single
dose of a MenACWY vaccine—
but only 60% had received a booster dose.4 Are you doing all you can to help
protect your patients?

According to 2021 CDC survey data, 91% of 17-year-olds had received a single
dose of a MenACWY vaccine—but only 60% had received a booster dose.4 Are you
doing all you can to help protect your patients?

SEE THE CDC RECOMMENDATIONS

 -

FDA-approved MENVEO dosing for adolescents and adults

PRIMARY
VACCINATION

SINGLE DOSE in adolescents and adults
aged 10 through 55 years1

SINGLE DOSE in adolescents and adults
aged 10 through 55 years1

BOOSTER
VACCINATION

SINGLE BOOSTER dose in individuals 15
through 55 years of age who are at continued
risk of meningococcal disease, at least 4
years after a prior dose of a MenACWY
vaccine1

SINGLE BOOSTER dose in individuals 15
through 55 years of age who are at continued
risk of meningococcal disease, at least 4
years after a prior dose of a MenACWY
vaccine1

 -

Order MENVEO

Are your patients missing their MenACWY booster dose?

Visit the GSK portal or contact your wholesaler/distributor to place an order
today.

Are your patients missing their MenACWY booster dose?

Visit the GSK portal or contact your wholesaler/distributor to place an order
today.

GO TO GSKDIRECT.COM

 -

What you can do

LEARN MORE
about meningococcal disease and what
you can do to help prevent it.
sd

FIND OUT MORE

HELP PROTECT
appropriate adolescent patients with a
primary AND booster dose of MENVEO as recommended by the CDC.

HELP PROTECT
appropriate adolescent patients with a
primary AND booster dose of MENVEO as recommended by the CDC.

EXPLORE BOOSTER DATA

DISCOVER THE HISTORY
of global heritage.
primary and booster dose of menveo
sdf

GET MORE INFORMATION

Vaccination may not protect all recipients.

CDC=Centers for Disease Control and Prevention.

Expand/Collapse
INDICATION & IMPORTANT SAFETY INFO
INDICATION

MENVEO is a vaccine indicated for active immunization to prevent invasive
meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and
W-135 in individuals 2 months through 55 years of age. MENVEO does not prevent
N. meningitidis serogroup B infections.

IMPORTANT SAFETY INFORMATION FOR MENVEO
 * Do not administer MENVEO to individuals with a severe allergic reaction (eg,
   anaphylaxis) to a previous dose of MENVEO, to any component of this vaccine,
   or to any other diphtheria toxoid-containing vaccine
 * Appropriate medical treatment must be available should an acute allergic
   reaction, including an anaphylactic reaction, occur following administration
   of MENVEO
 * Syncope (fainting) has occurred in association with administration of MENVEO.
   Procedures should be in place to avoid injury from fainting
 * Some individuals with altered immunocompetence, including some individuals
   receiving immunosuppressant therapy, may have reduced immune responses to
   MENVEO
 * Individuals with certain complement deficiencies and individuals receiving
   treatment that inhibits terminal complement activation (for example,
   eculizumab) are at increased risk for invasive disease caused by Neisseria
   meningitidis serogroups A, C, Y, and W, even if they develop antibodies
   following vaccination with MENVEO
 * Guillain-Barré syndrome (GBS) has been reported in temporal relationship
   following administration of another US-licensed meningococcal quadrivalent
   polysaccharide conjugate vaccine. The decision to administer MENVEO to
   individuals with a history of GBS should take into account the expected
   benefits and potential risks
 * Apnea following intramuscular vaccination has been observed in some infants
   born prematurely. A decision about when to administer MENVEO to an infant
   born prematurely should be based on consideration of the individual infant’s
   medical status and the potential benefits and possible risks of vaccination
 * Common solicited adverse reactions with MENVEO among children initiating
   vaccination: at 2 months of age and receiving the four-dose series were
   tenderness and erythema at injection site, irritability, sleepiness,
   persistent crying, change in eating habits, vomiting, and diarrhea; at 7
   months through 23 months of age and receiving the two-dose series were
   tenderness and erythema at injection site, irritability, sleepiness,
   persistent crying, change in eating habits, and diarrhea; at 2 through 10
   years of age who received MENVEO were injection site pain, erythema,
   irritability, induration, sleepiness, malaise, and headache. Common solicited
   adverse reactions among adolescents and adults aged 11 through 55 years who
   received a single dose of MENVEO were pain at the injection site, headache,
   myalgia, malaise, and nausea. Across all age groups, some events were severe.
   Similar rates of solicited adverse reactions among adolescents and adults
   were observed following a single booster dose
 * In two clinical studies, there were no notable differences in frequency and
   severity of solicited adverse reactions in individuals who received MENVEO
   1-vial presentation compared to individuals who received the 2-vial
   presentation
 * Vaccination with MENVEO may not result in protection in all vaccine
   recipients

Please see full Prescribing Information for MENVEO.

References

 1. Prescribing Information for MENVEO.
 2. Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal vaccination:
    recommendations of the Advisory Committee on Immunization Practices, United
    States, 2020. MMWR. 2020;69(RR-9):1-41.
 3. Recommended child and adolescent immunization schedule for ages 18 years or
    younger, United States, 2023. Centers for Disease Control and Prevention.
    Reviewed February 10, 2023. Accessed March 6, 2023.
    https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html
 4. Pingali C, Yankey D, Elam-Evans LD, et al. National vaccination coverage
    among adolescents aged 13–17 years—National Immunization Survey-Teen, United
    States, 2021. MMWR. 2022;71(35):1101-1108.

Utility Links
Legal Notices
Privacy Notice
Interest-based Ads
Contact Us
Your Privacy Choices

Trademarks are property of their respective owners.

This website is funded and developed by GSK.
This site is intended for US healthcare professionals only.
©2023 GSK or licensor.
MNVWCNT230005 April 2023
Produced in USA.

Expand/Collapse
INDICATION & IMPORTANT SAFETY INFO
INDICATION

INDICATION

MENVEO is a vaccine indicated for active immunization to prevent invasive
meningococcal disease caused by Neisseria meningitidis serogroups

MENVEO is a vaccine indicated for active immunization to prevent invasive
meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and
W-135 in individuals 2 months through 55 years of age. MENVEO does not prevent
N. meningitidis serogroup B infections.

IMPORTANT SAFETY INFORMATION FOR MENVEO

IMPORTANT SAFETY INFORMATION FOR MENVEO

 * Do not administer MENVEO to individuals with a severe allergic reaction (eg,
   anaphylaxis) to a previous dose of MENVEO, to any component of this vaccine,
   or to any other diphtheria toxoid-containing vaccine

 * Do not administer MENVEO to individuals with a severe allergic reaction (eg,
   anaphylaxis) to a previous dose of MENVEO, to any component of this vaccine,
   or to any other diphtheria toxoid-containing vaccine
 * Appropriate medical treatment must be available should an acute allergic
   reaction, including an anaphylactic reaction, occur following administration
   of MENVEO
 * Syncope (fainting) has occurred in association with administration of MENVEO.
   Procedures should be in place to avoid injury from fainting

Back to Top

This site uses cookies and similar technologies (collectively, "cookies") to
enhance your website experience and track the site's performance. These cookies
are automatically enabled. By using this site, you agree to our use of these
cookies in accordance with our Privacy Notice. Click on Privacy Choices below to
manage your preferences, including to opt out of the sale or sharing of your
information.

Privacy Choices

Managing Privacy Options

OPT OUT OF SALE AND SHARING OF INFORMATION

Your state law may allow you the right to opt out of the sale or sharing of your
personal information for targeted advertising. You may opt out of such sale or
share via the toggle available to you for "Targeting Cookies," and selecting the
"Confirm my choices” button below. To limit sale or sharing of your information
for targeting advertising offline, please see the "Cookies and Targeted
Advertising Choices," section in the Privacy Notice and submit the required
form.

Strictly Necessary Cookies Always Active

Necessary for the website to function appropriately, such as to store session
data during a website visit, to manage cookie and tag preferences, and to
protect the security of the website. In addition, some of these cookies are set
in response to actions made by you which amount to a request for services, such
as setting your privacy preferences, logging in, or filling in forms.

Performance Cookies Always Active

Enable the website to provide enhanced functionality and personalization, such
as by helping us to measure how many visitors come to our websites, what sites
our website visitors come from, and how often certain pages on our website are
viewed. These cookies may be set by us or by third party providers, like our
analytics service providers, whose services we have added to our pages.

Targeting Cookies

Allow us to target and re-target you with relevant advertising. We and our
advertising partners use information collected through these technologies to
infer your interests in order to serve you more relevant advertisements on other
sites. If you don’t allow these cookies, you will receive advertising, but it
may be less relevant to you.

Confirm my choices